It’s time to manage hyperkalaemia and maintain RAASi therapy for cardiorenal protection in HF and CKD.
This webpage is intended for UK HCPs only. Contains promotional material developed and funded by AstraZeneca. Prescribing information and adverse event reporting information is found at the bottom of the following page.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
GB-65930 April 2025
Stroke Research in China: A spotlight on the CHANCE trials
MAT-GLB-2402431-1.0-05/2024
MAT-US-2406686 v1.0 - P Expiration Date: 09/30/2026
Accredited By International Congress For Health Specialties
Accredited By International Congress For Health Specialties